Want to see PHAR full AI Analyst Report?
PHAR Stock Chart & Stats
$17.34
>-$0.01(-0.06%)
At close: 4:00 PM EST
$17.34
>-$0.01(-0.06%)
Day’s Range― - ―
52-Week Range$9.30 - $21.34
Previous CloseN/A
Volume11.43K
Average Volume (3M)8.17K
Market Cap
$1.02B
Enterprise Value$980.20M
Total Cash (Recent Filing)$170.90M
Total Debt (Recent Filing)$116.20M
Price to Earnings (P/E)73.5
Beta0.47
Next Earnings
Jul 30, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding70,778,120
10 Day Avg. Volume6,404
30 Day Avg. Volume8,169
Financial Highlights & Ratios
PEG Ratio-3.60
Price to Book (P/B)4.55
Price to Sales (P/S)3.35
P/FCF Ratio25.55
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.65
Enterprise Value/Gross Profit3.01
Enterprise Value/Ebitda22.44
Forecast
1Y Price Target
$38.00Price Target Upside119.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.2
Revenue Forecast (FY)$403.52M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Improving Cash GenerationSustained gross margins near 90% paired with a return to positive free cash flow indicate a durable cash-generative product mix. This margin profile buffers profitability against price pressure and supports funding of R&D, commercial expansion and balance-sheet flexibility over the next 2–6 months.
EU Approval Expands Joenja MarketEU-wide marketing authorization materially expands addressable APDS markets and gives Pharming first-in-class status in Europe. A Germany launch and subsequent national reimbursements create a durable revenue channel and validate the commercial case for further launches and payer negotiations.
Meaningful Regulatory & Pipeline CatalystsA defined regulatory timetable and multiple near-term readouts create durable upside optionality: pediatric approval would broaden label and patient base, Phase II data can expand indications, and napazimone enrollment progress supports a 2027 readout, strengthening long-term growth visibility.
Bears Say
RUCONEST Sales HeadwindsA meaningful decline in the legacy cash engine highlights dependency risk: RUCONEST weakness from inventory cycles, market exits and new oral competitors reduces near-term revenue resilience and increases execution risk if market share erosion persists across multiple reorder cycles.
Joenja Commercial Scale Still LimitedDespite strong percentage growth, Joenja's current patient base and revenue remain small, making future topline gains contingent on pediatric approval, successful European/Japan launches and continued conversion. Execution risk in patient ID and reimbursement could delay durable scaling.
Cash Conversion & Working Capital SensitivityOCF below net income signals part of earnings tied to working capital or timing items, reducing cash quality. This weakens near-term financial flexibility and raises the potential for volatility in free cash flow if receivables, inventory or timing dynamics reverse during growth or competitive stress.
Pharming Group News
PHAR FAQ
What was Pharming Group Nv’s price range in the past 12 months?
Pharming Group Nv lowest stock price was $9.30 and its highest was $21.34 in the past 12 months.
What is Pharming Group Nv’s market cap?
Pharming Group Nv’s market cap is $1.02B.
When is Pharming Group Nv’s upcoming earnings report date?
Pharming Group Nv’s upcoming earnings report date is Jul 30, 2026 which is in 20 days.
How were Pharming Group Nv’s earnings last quarter?
Pharming Group Nv released its earnings results on May 07, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.071.
Is Pharming Group Nv overvalued?
According to Wall Street analysts Pharming Group Nv’s price is currently Undervalued.
Does Pharming Group Nv pay dividends?
Pharming Group Nv does not currently pay dividends.
What is Pharming Group Nv’s EPS estimate?
Pharming Group Nv’s EPS estimate is 0.06.
How many shares outstanding does Pharming Group Nv have?
Pharming Group Nv has 70,778,120 shares outstanding.
What happened to Pharming Group Nv’s price movement after its last earnings report?
Pharming Group Nv reported an EPS of -$0.07 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went down -26.829%.
Which hedge fund is a major shareholder of Pharming Group Nv?
Currently, no hedge funds are holding shares in PHAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharming Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (119.15% Upside)
$38.00 (119.15% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.25%
12-Months-Change
Fundamentals
Return on Equity
4.75%
Trailing 12-Months
Asset Growth
21.38%
Trailing 12-Months
Company Description
Pharming Group Nv
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Company Deck
PHAR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive outlook driven by strong Joenja growth, meaningful pipeline and regulatory catalysts, and demonstrated cost discipline with positive operating cash flow. These positives offset near‑term revenue variability driven mainly by expected RUCONEST inventory normalization, strategic market exits and short‑term competitive pressure. Management reaffirmed full‑year guidance and highlighted multiple upcoming clinical and commercial events that could drive upside.View all PHAR earnings summariesPHAR Stock 12 Month Forecast
Average Price Target
$38.00
▲(119.15% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.06% Other Institutional Investors
99.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---